2020
DOI: 10.1038/d41586-020-02886-1
|View full text |Cite
|
Sign up to set email alerts
|

How researchers are revamping antimicrobial drugs

Abstract: is rethinking ways to search for drug candidates that overcome drug resistance. KELVIN MA/TUFTS UNIV.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 5 publications
0
4
0
Order By: Relevance
“…[ 2 ] Annually, drug‐resistant infections cause at least 700 000 deaths globally each year; and this number is predicted to increase to 10 million by 2050. [ 3 ] To overcome this challenge, it is imperative to offer viable options to fight against antimicrobial resistance (AMR). Among the various strategies, antibiotic‐free strategies have become a promising approach to respond to the current antibacterial dilemma.…”
Section: Introductionmentioning
confidence: 99%
“…[ 2 ] Annually, drug‐resistant infections cause at least 700 000 deaths globally each year; and this number is predicted to increase to 10 million by 2050. [ 3 ] To overcome this challenge, it is imperative to offer viable options to fight against antimicrobial resistance (AMR). Among the various strategies, antibiotic‐free strategies have become a promising approach to respond to the current antibacterial dilemma.…”
Section: Introductionmentioning
confidence: 99%
“…On the biological side, it is likely that the antibiotic boom of the 1950s–1990s was only caused by the “low-hanging fruit” nature of bacterial targets and antibiotic molecules [ 2 ]. Financially, there is stark contrast between funding, such as the Combating Antibiotic-Resistant bacteria Biopharmaceutical Accelerator and its USD 500 million to support research [ 342 ], and the USD 2.3 billion it costs to develop a new drug on average. Governmental plans to “jump-(re)start” antibiotic R&D consist mostly of giving away public monies to the same companies that are at the root of the problem.…”
Section: Non-canonical Approaches To Fight Resistant Infectionsmentioning
confidence: 99%
“…These phytoconstituents or SMs are non-hazardous, eco-friendly, and are widely known for their innumerable applications for example nutraceuticals, agriculture, perfumery, personal hygiene, pharmaceutical and cosmeceutical [ [1] , [2] , [3] , [4] , [5] , [6] ]. In order to counter the problem of resistance produced by the present antiviral and antibacterial drugs and owing to the toxic nature of most of synthetic antioxidants or preservatives, from precedent decade, the extensive search for plant based novel antibacterial, antiviral and antioxidants agents is underway [ [7] , [8] , [9] , [10] , [11] ]. Therefore, in the coming future there are innumerable projections to pursuit for the diverse array of natural bioactive antibacterial, antiviral and antioxidant agents of plant origin [ [12] , [13] , [14] ].…”
Section: Introductionmentioning
confidence: 99%